Randomized single-blind clinical trial of intradermal methylene blue on pain reduction after open diathermy haemorrhoidectomy

What Was Tested

Researchers studied Methylene blue (non-peptide stack partner) in this randomized controlled trial publication.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Patients were asked to fill in a pain diary with a visual analogue scale.

How the Study Was Run

The design is described as randomized, single-blind and placebo-controlled.

Because people in this Methylene blue (non-peptide stack partner) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Only one side, usually the participants, was kept unaware of whether Methylene blue (non-peptide stack partner) was given.

Some participants received a placebo instead of Methylene blue (non-peptide stack partner), giving a reference point.

A randomized, prospective, single-blind placebo-controlled trial was conducted.

The primary outcome measure was pain score and analgesic use.

What Was Measured

Topics PubMed links to this paper include Analgesics, Bupivacaine, Electrocoagulation, Hemorrhoidectomy, Hemorrhoids, Injections, Intradermal and Methylene Blue.

The authors tagged it with the keywords Milligan Morgan haemorrhoidectomy, open haemorrhoidectomy and post operative pain.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Methylene blue (non-peptide stack partner).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland), a journal based in England.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.